Biopharma 4.0 is often presented as an all-or-nothing proposition, when in fact its components have all been around for a while and have independent value. It appears the major challenge will be ...

Moving away from fed-batch has significant sustainability and cost-saving benefits, according to industry working groups.

ISA106 started with the goal of developing standards, recommended practices, and technical reports on the design and implementation of procedures for automating continuous process operations. The ...

In the manufacture of biotherapeutic drugs, the goal is to maximize production while minimizing costs, even though achieving this goal may involve a difficult transition—specifically, a transition ...

This activity was supported by Contract/Grant No. HHSP233201400020B between the National Academy of Sciences and the Department of Health and Human Services. Any opinions, findings, conclusions, or ...

Andreas Eschbach is the founder and CEO of eschbach, a software company that helps production teams work smarter and enhance collaboration. Within the process industry, the chemical and pharmaceutical ...

A photo of technicians working in front of a process train. Novartis's continuous manufacturing center in Basel, Switzerland, replicates an end-to-end manufacturing process developed at the ...

DIANT is a startup co-founded by Antonio Costa, Ph.D. and Diane Burgess, Ph.D. In 2020, DIANT licensed their core manufacturing technology from UConn and was granted a patent on the technology earlier ...

Historically, pharmaceutical products have been produced in a traditional ‘batch’ system, in which every operation is executed separately using a defined quantity of materials. In batch manufacturing ...